


BEST AVAILABLE COPY

Goldstein et al.
Application Serial No. 10/066,040
Page 5

CLAIM LISTING

1. (Currently Amended) A compound selected from the group of compounds represented by Formula (I):



wherein:

R¹ is hydrogen or acyl;

R² is hydrogen or alkyl;

A and B are simultaneously an aryl or a heteroaryl ring;

R³ is selected from the group consisting of:

- (a) optionally substituted heterocyclyl;
- ~~(b) optionally substituted aryl or heteroaryl;~~
- (c) heteroalkenyl;
- (r) heteroalkynyl;
- (c) optionally substituted heterocyclylalkyl;
- (f) optionally substituted heterocyclylalkenyl;
- (g) optionally substituted heterocyclylalkynyl;
- (h) optionally substituted heterocyclylalkoxy, cyclyloxy or heterocyclyloxy;
- (i) optionally substituted heterocyclylalkylamino;
- (j) optionally substituted heterocyclylalkylcarbonyl;
- (k) -Y-(alkylene)-R⁹ where:
Y is a single bond, -O-, -NH- or -S(O)_n- (where n is an integer from 0 to 2); and

BEST AVAILABLE COPY

Goldstein et al.
Application Serial No. 10/066,040
Page 6

BEST AVAILABLE COPY

R^9 is cyano, optionally substituted heteroaryl, $-\text{COOH}$, $-\text{COR}^{10}$, $[-\text{C}(\text{OR}^{11})_2]$, $-\text{CONR}^{12}\text{R}^{13}$, $-\text{SO}_2\text{R}^{14}$, $-\text{SO}_2\text{NR}^{15}\text{R}^{16}$, $-\text{NHSO}_2\text{R}^{17}$ or $-\text{NHSO}_2\text{NR}^{18}\text{R}^{19}$, where R^{10} is optionally substituted heterocycle, ~~R^{11} is alkyl~~, and R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are, independently of each other, hydrogen, alkyl or heteroalkyl;

- (l) $-\text{C}(=\text{NR}^{20})(\text{NR}^{21}\text{R}^{22})$ where R^{20} , R^{21} and R^{22} independently represent hydrogen, alkyl or hydroxy, or R^{20} and R^{21} together are $-(\text{CH}_2)_n-$ where n is 2 or 3 and R^{22} is hydrogen or alkyl;
- (m) $-\text{NHC}(\text{X})\text{NR}^{23}\text{R}^{24}$ where X is $-\text{O}-$ or $-\text{S}-$, and R^{23} and R^{24} are, independently of each other, hydrogen, alkyl or heteroalkyl;
- (n) $-\text{CONR}^{25}\text{R}^{26}$ where R^{25} and R^{26} independently represent hydrogen, alkyl, heteroalkyl or optionally substituted heterocyclylalkyl, or R^{25} and R^{26} together with the nitrogen to which they are attached form an optionally substituted heterocyclyl ring;
- (o) cycloalkylalkyl, ~~cycloalkylalkynyl~~, cycloalkylalkenyl and cycloalkylalkynyl, all optionally substituted with alkyl, halo, hydroxy or amino;
- (p) arylaminoalkylene or heteroarylaminomethylene;
- (q) $\text{Z-alkylene-NR}^{30}\text{R}^{31}$ or $\text{Z-alkylene-OR}^{32}$ where Z is $-\text{O}-$, and R^{30} , R^{31} and R^{32} are independently of each other, hydrogen, alkyl or heteroalkyl;
- (r) $-\text{OC}(\text{O})\text{-alkylene-CO}_2\text{H}$ [[,]] or $-\text{OC}(\text{O})\text{-NR}'\text{R}''$ (where R' and R'' are independently hydrogen or alkyl);
- (s) heteroarylalkenylene or heteroarylalkynylene; and
- (t) heteroalkylamino;

R^4 is selected from the group consisting of:

- (a) hydrogen;
- (b) halo;
- (c) alkyl;

Goldstein et al.
Application Serial No. 10/066,040
Page 7

BEST AVAILABLE COPY

(d) alkoxy; and

(e) hydroxy;

R^5 is selected from the group consisting of:

(a) hydrogen;

(b) halo;

(c) alkyl;

(d) haloalkyl;

(e) thioalkyl;

(f) hydroxy;

(g) amino;

(h) alkylamino;

(i) dialkylamino;

(j) heteroalkyl;

(k) optionally substituted heterocycle;

(l) optionally substituted heterocyclalkyl;

(m) optionally substituted heterocyclalkoxy;

(n) alkylsulfonyl;

(o) aminosulfonyl, mono-alkylaminosulfonyl or di-alkylaminosulfonyl;

(p) heteroalkoxy; and

(q) carboxy;

R^6 is selected from the group consisting of:

(a) hydrogen;

(b) halo;

(c) alkyl; and

(d) alkoxy; and

prodrugs, individual isomers, mixtures of isomers and pharmaceutically acceptable salts thereof.

2. (Currently Amended) The compound of Claim 1 wherein R^3 is:

Goldstein et al.
Application Serial No. 10/066,040
Page 8

BEST AVAILABLE COPY

- (a) optionally substituted heterocyclyl;
 - (b) aryl or heteroaryl optionally substituted with a substituent selected from halo, alkyl, amino, alkoxy, carboxy, lower alkoxy carbonyl, $\text{SO}_2\text{R}'$ (where R' is alkyl) or $\text{SO}_2\text{NHR}''$ (where R' and R'' are independently hydrogen or alkyl);
 - (c) heteroalkenyl;
 - (d) heteroalkylamino;
 - (e) optionally substituted heterocyclylalkyl or heterocyclyloxy;
 - (f) optionally substituted heterocyclylalkenyl;
 - (g) optionally substituted heterocyclylalkynyl;
 - (h) optionally substituted heterocyclylalkoxy;
 - (i) optionally substituted heterocyclylalkylamino;
 - (j) optionally substituted heterocyclylalkylcarbonyl;
 - (k) $-\text{Y}-(\text{alkylene})-\text{R}^9$ where Y is a single bond $-\text{O}-$ or $-\text{NH}-$ and R^9 is optionally substituted heteroaryl, $-\text{CONR}^{12}\text{R}^{13}$, SO_2R^{14} , $-\text{SO}_2\text{NR}^{15}\text{R}^{16}$, $-\text{NHSO}_2\text{R}^{17}$ or $-\text{NHISO}_2\text{NR}^{18}\text{R}^{19}$ where R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are independently of each other hydrogen, alkyl or heteroalkyl,
 - (l) cycloalkylalkyl, ~~cycloalkylalkynyl~~ cycloalkylalkenyl and cycloalkylalkynyl, all optionally substituted with alkyl, halo, hydroxy or amino;
 - (m) arylaminoalkylene or heteroarylaminoalkylene; or
 - (n) $\text{Z}-(\text{alkylene})-\text{NR}^{30}\text{R}^{31}$ where Z is $-\text{O}-$, and R^{30} and R^{31} are independently of each other, hydrogen, alkyl or heteroalkyl.
3. (Original) The compound of Claim 2 wherein R^1 and R^2 are hydrogen; and B is phenyl.
4. (Original) The compound of Claim 3 wherein A is phenyl.
5. (Original) The compound of Claim 4 wherein R^4 is hydrogen; and R^5 is halo or alkyl.


BEST AVAILABLE COPY

Goldstein et al.
Application Serial No. 10/066,040
Page 9

6. (Original) The compound of Claim 5 wherein R^5 is chloro, fluoro or methyl; and R^6 is hydrogen, chloro, fluoro, methyl or methoxy.
7. (Original) The compound of Claim 5, wherein R^3 is optionally substituted heteroaryl.
8. (Original) The compound of Claim 7, wherein R^3 is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, N-oxidopyridin-2-yl, N-oxidopyridin-3-yl, N-oxidopyridin-4-yl or pyridon-2-yl, all optionally substituted.
9. (Original) The compound of Claim 8, wherein R^3 is at the 3-position.
10. (Original) The compound of Claim 9, wherein R^5 is 4-F and R^6 is hydrogen.
11. (Original) The compound of Claim 9, wherein R^5 is 2-Me and R^6 is hydrogen.
12. (Original) The compound of Claim 5, wherein R^3 is optionally substituted phenyl.
13. (Original) The compound of Claim 12, wherein R^3 is 3-sulfamoylphenyl, 3-methylsulfonylphenyl, 3-carboxyphenyl or 3-ethoxycarbonylphenyl
14. (Original) The compound of Claim 13, wherein R^3 is at the 3-position
15. (Original) The compound of Claim 14, wherein R^5 is 4-F and R^6 is hydrogen.
16. (Currently Amended) A compound selected from the group of compounds represented by the Formula:

Goldstein et al.
Application Serial No. 10/066,040
Page 10

BEST AVAILABLE COPY



wherein:

R^5 is halo or alkyl; and

R^3 is:

- (a) heteroalkylamino;
- (b) optionally substituted heterocyclalkyl;
- (c) optionally substituted heterocyclalkoxy;
- (d) optionally substituted heterocyclalkylamino;
- (e) $-Y-(alkylene)-R^9$ where Y is a single bond, $-O-$ or $-NH-$ and R^9 is optionally substituted heteroaryl, $-CONR^{12}R^{13}$, SO_2R^{14} , $-SO_2NR^{15}R^{16}$, $NIISO_2R^{17}$ or $-NHISO_2NR^{18}R^{19}$ where R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are independently of each other hydrogen, alkyl or heteroalkyl; or
- (f) $Z-alkylene-NR^{30}R^{31}$ where Z is $-O-$, and R^{30} and R^{31} are independently of each other, hydrogen, alkyl or heteroalkyl;[[;]]
- (g) ~~heteroaryl selected from~~ pyridinyl, N-oxidopyridinyl or pyridonyl; or
- (h) ~~substituted phenyl selected from~~ sulfamoylphenyl, methylsulfonylphenyl, carboxyphenyl or ethoxycarbonylphenyl; and

prodrugs, individual isomers, mixtures of isomers and pharmaceutically acceptable salts thereof.

17-21. (Canceled)

22. (Previously Presented) The compound of Claim 16, wherein R^3 is heteroalkylamino.

Goldstein et al.
Application Serial No. 10/066,040
Page 11


BEST AVAILABLE COPY

23. (Currently Amended) The compound of Claim 22, wherein R^3 is at the 3-position and is selected from the group consisting of ~~3-dimethylaminopropoxy, 2-dimethylaminoethoxy, 2-hydroxyethoxy, 2,3-dihydroxypropoxy, 2-dimethylaminooethylamino and 3-dimethylaminopropylamino.~~
24. (Canceled)
25. (Original) The compound of Claim 16, wherein R^3 is optionally substituted heterocyclalkyl, optionally substituted heterocyclalkoxy or optionally substituted heterocyclalkylamino.
26. (Original) The compound of Claim 25, wherein R^3 is at the 3-position and is selected from the group consisting of 3-(morpholin-4-yl)propoxy, 2-(morpholin-4-yl)ethoxy, 2-(2-oxo-pyrrolidin-1-yl)ethoxy, 3-(morpholin-4-yl)propyl, 2-(morpholin-4-yl)ethyl, 4-(morpholin-4-yl)butyl, 3-(morpholin-4-yl)propylamino, 2-(morpholin-4-yl)ethylamino, 4-hydroxypiperidinylmethyl, 2-(S,S-dioxo-thiamorpholin-4-yl)ethyl, 3-(S,S-dioxo-thiamorpholin-4-yl)propyl and N-methylpiperazinylmethyl.
27. (Canceled)
28. (Original) The compound of Claim 16 wherein R^3 is $-Y-(alkylene)-R^9$ where Y is a single bond, $-O-$ or $-NH-$ and R^9 is optionally substituted heteroaryl, $-CONR^{12}R^{13}$, SO_2R^{14} , $SO_2NR^{15}R^{16}$, $NHISO_2R^{17}$ or $NHSO_2NR^{18}R^{19}$ where R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are independently of each other hydrogen, alkyl or heteroalkyl.
29. (Original) The compound of Claim 28, wherein Y is a single bond and R^9 is SO_2R^{14} or $SO_2NR^{15}R^{16}$.

Goldstein et al.
Application Serial No. 10/066,040
Page 12

BEST AVAILABLE COPY

30. (Original) The compound of Claim 29 wherein R^3 is methylsulfonyl ethyl or sulfamoyl ethyl.
31. (Canceled)
32. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable excipient.
- 33-38. (Canceled)
39. (Currently Amended) A compound selected from the group of compounds represented by Formula (I):



wherein:

A and B ~~each independently is~~ are simultaneously an aryl or a heteroaryl ring;

R^1 is hydrogen or acyl;

R^2 is hydrogen or alkyl;

R^3 is:

- (a) heteroalkylamino;
- (b) optionally substituted heterocyclalkyl;
- (c) optionally substituted heterocyclalkoxy;
- (d) optionally substituted heterocyclalkylamino;
- (e) $-Y-(alkylene)-R^9$ where Y is a single bond, $-O-$ or $-NH-$ and R^9 is optionally substituted heteroaryl, $-CONR^{12}R^{13}$, SO_2R^{14} , $-SO_2NR^{15}R^{16}-$

Goldstein et al.
Application Serial No. 10/066,040
Page 13

BEST AVAILABLE COPY

$\text{NHSO}_2\text{R}^{17}$ or $\text{-NHSO}_2\text{NR}^{18}\text{R}^{19}$ where R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are independently of each other hydrogen, alkyl or heteroalkyl; or

(f) $\text{Z-alkylene-NR}^{30}\text{R}^{31}$ where Z is -O- , and R^{30} and R^{31} are independently of each other, hydrogen, alkyl or ~~heteroalkyl~~ heteroalkyl;

(g) ~~heteroaryl selected from~~ pyridinyl, N-oxidopyridinyl or pyridonyl; or

(h) ~~substituted phenyl selected from~~ sulfamoylphenyl,

methylsulfonylphenyl, carboxyphenyl or ethoxycarbonylphenyl; ~~and~~

~~prodrugs, individual isomers, mixtures of isomers and pharmaceutically acceptable salts thereof.~~

R^4 is selected from the group consisting of:

- (a) hydrogen;
- (b) halo;
- (c) alkyl;
- (d) alkoxy; and
- (e) hydroxy;

R^5 is selected from the group consisting of:

- (a) hydrogen;
- (b) halo;
- (c) alkyl;
- (d) haloalkyl;
- (e) thioalkyl;
- (f) hydroxy;
- (g) amino;
- (h) alkylamino;
- (i) dialkylamino;
- (j) heteroalkyl;
- (k) optionally substituted heterocycle;
- (l) optionally substituted heterocyclalkyl;
- (m) optionally substituted heterocyclalkoxy;

Goldstein et al.
Application Serial No. 10/066,040
Page 14

BEST AVAILABLE COPY

- (n) alkylsulfonyl;
- (o) aminosulfonyl, mono-alkylaminosulfonyl or di-alkylaminosulfonyl;
- (p) heteroalkoxy; and
- (q) carboxy;

R^6 is selected from the group consisting of:

- (a) hydrogen;
- (b) halo;
- (c) alkyl; and
- (d) alkoxy; and

prodrugs, individual isomers, mixtures of isomers and pharmaceutically acceptable salts thereof.